Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.
|Articles|December 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 12
- Volume 15
- Issue 12
Pharmion Purchases Cabrellis, US Developer of Amrubicin
Pharmion Corporation has acquired Cabrellis Pharmaceuticals and gained US and European rights to amrubicin, a third-generation synthetic anthracycline currently in phase II trials for small-cell lung cancer in North America and Europe.
Advertisement
BOULDER, ColoradoPharmion Corporation has acquired Cabrellis Pharmaceuticals and gained US and European rights to amrubicin, a third-generation synthetic anthracycline currently in phase II trials for small-cell lung cancer in North America and Europe.
Articles in this issue
almost 20 years ago
Best Rx Most Cost-Effective: RTOGalmost 20 years ago
Grape Seed Found to Be a Natural Aromatase Inhibitoralmost 20 years ago
Drug Combination Prevents ER-Negative Tumors in Micealmost 20 years ago
Democrats' Agenda May Stifle Efforts for More Ca Fundingalmost 20 years ago
No Loss of Efficacy With Synchronous Chemotherapy/ESPalmost 20 years ago
'Share Care' Difficult for Ca Survivors and Their Oncologistsalmost 20 years ago
Biomarkers Panel Promising for Detecting Pancreatic Caalmost 20 years ago
Preop Avastin/Tarceva in RCCalmost 20 years ago
Reovirus Agent Shows Activity in Phase I TrialAdvertisement
Related to this article
Chinmay Jani, MD, discusses ASCO 2026 data on lung cancer trends in younger adults and why this group has been overlooked.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5